FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005655584> ?p ?o ?g. }

• W2005655584 abstract "In a previous phase II randomized study, a cisplatin/gemcitabine/vinorelbine (PGV) regimen produced a 50-week median survival time (MST) in advanced non small-cell lung cancer (NSCLC) patients. The present trial was planned to randomly compare the outcome of patients treated with this new triplet regimen with those of patients receiving either cisplatin plus vinorelbine (PV) or cisplatin plus gemcitabine (PG) doublet combinations. One hundred eighty patients with stage IIIB (76) or IV (104) disease, aged <or= 70 years, and with Eastern Cooperative Oncology Group performance status (ECOG PS) <or= 1, were randomly allocated to receive: cisplatin, 50 mg/m2 plus gemcitabine, 1000 mg/m2 plus vinorelbine, 25 mg/m2 (PGV) on days 1 and 8 every 3 weeks; cisplatin, 100 mg/m2 on day 1 plus gemcitabine, 1000 mg/m2 (PG) on days 1, 8, and 15 every 4 weeks; cisplatin, 120 mg/m2 on days 1 and 29 plus vinorelbine, 30 mg/m2/week (PV). At the planned interim analysis, the MST of patients in the PGV, PG, and PV arms was 51, 42, and 35 weeks, respectively. The hazard of death (Cox analysis) for patients receiving PGV compared with those receiving PV was 0.35 (95% confidence index [CI], 0.16-0.77, P = 0.0058). The response rate was 47% in the PGV arm, 30% in the PG arm, and 25% in the PV arm. Severe neutropenia (75% vs. 45%), and vomiting (50% vs. 15%) significantly affected more patients in the PV than in the PGV arm. Since the difference in survival met early stopping rules, accrual to the PV arm was suspended. Enrollment still continues in the PGV and PG arms to ascertain whether the triplet regimen has a more significant effect on survival than that produced with the PG regimen." @default.
• W2005655584 created "2016-06-24" @default.
• W2005655584 creator A5007383961 @default.
• W2005655584 creator A5015849958 @default.
• W2005655584 creator A5036019590 @default.
• W2005655584 creator A5038579170 @default.
• W2005655584 creator A5038819793 @default.
• W2005655584 creator A5043924324 @default.
• W2005655584 creator A5049064112 @default.
• W2005655584 creator A5054473930 @default.
• W2005655584 creator A5056559714 @default.
• W2005655584 creator A5057266247 @default.
• W2005655584 creator A5069508770 @default.
• W2005655584 creator A5073695437 @default.
• W2005655584 creator A5081385647 @default.
• W2005655584 creator A5089737234 @default.
• W2005655584 creator A5090055323 @default.
• W2005655584 creator A5091626402 @default.
• W2005655584 date "2000-02-01" @default.
• W2005655584 modified "2023-09-27" @default.
• W2005655584 title "Interim Analysis of a Phase III Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine vs. Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer. A Southern Italy Cooperative Oncology Group Study" @default.
• W2005655584 cites W1562321687 @default.
• W2005655584 cites W1580788756 @default.
• W2005655584 cites W1837121308 @default.
• W2005655584 cites W1842046266 @default.
• W2005655584 cites W1848316250 @default.
• W2005655584 cites W1874925441 @default.
• W2005655584 cites W1933707312 @default.
• W2005655584 cites W1934366775 @default.
• W2005655584 cites W1938837918 @default.
• W2005655584 cites W1961110209 @default.
• W2005655584 cites W2001662271 @default.
• W2005655584 cites W2080459294 @default.
• W2005655584 cites W2129793485 @default.
• W2005655584 cites W2146014573 @default.
• W2005655584 cites W2167805334 @default.
• W2005655584 cites W2168111179 @default.
• W2005655584 cites W2227314491 @default.
• W2005655584 cites W2409921532 @default.
• W2005655584 cites W2417484160 @default.
• W2005655584 cites W2434992030 @default.
• W2005655584 cites W2576744703 @default.
• W2005655584 cites W3041047318 @default.
• W2005655584 doi "https://doi.org/10.3816/clc.2000.n.003" @default.
• W2005655584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14733645" @default.
• W2005655584 hasPublicationYear "2000" @default.
• W2005655584 type Work @default.
• W2005655584 sameAs 2005655584 @default.
• W2005655584 citedByCount "8" @default.
• W2005655584 countsByYear W20056555842013 @default.
• W2005655584 countsByYear W20056555842016 @default.
• W2005655584 crossrefType "journal-article" @default.
• W2005655584 hasAuthorship W2005655584A5007383961 @default.
• W2005655584 hasAuthorship W2005655584A5015849958 @default.
• W2005655584 hasAuthorship W2005655584A5036019590 @default.
• W2005655584 hasAuthorship W2005655584A5038579170 @default.
• W2005655584 hasAuthorship W2005655584A5038819793 @default.
• W2005655584 hasAuthorship W2005655584A5043924324 @default.
• W2005655584 hasAuthorship W2005655584A5049064112 @default.
• W2005655584 hasAuthorship W2005655584A5054473930 @default.
• W2005655584 hasAuthorship W2005655584A5056559714 @default.
• W2005655584 hasAuthorship W2005655584A5057266247 @default.
• W2005655584 hasAuthorship W2005655584A5069508770 @default.
• W2005655584 hasAuthorship W2005655584A5073695437 @default.
• W2005655584 hasAuthorship W2005655584A5081385647 @default.
• W2005655584 hasAuthorship W2005655584A5089737234 @default.
• W2005655584 hasAuthorship W2005655584A5090055323 @default.
• W2005655584 hasAuthorship W2005655584A5091626402 @default.
• W2005655584 hasConcept C126322002 @default.
• W2005655584 hasConcept C143998085 @default.
• W2005655584 hasConcept C168563851 @default.
• W2005655584 hasConcept C207103383 @default.
• W2005655584 hasConcept C2776256026 @default.
• W2005655584 hasConcept C2776694085 @default.
• W2005655584 hasConcept C2777063308 @default.
• W2005655584 hasConcept C2778239845 @default.
• W2005655584 hasConcept C2780258809 @default.
• W2005655584 hasConcept C2780350996 @default.
• W2005655584 hasConcept C2781413609 @default.
• W2005655584 hasConcept C31760486 @default.
• W2005655584 hasConcept C44249647 @default.
• W2005655584 hasConcept C61943457 @default.
• W2005655584 hasConcept C71924100 @default.
• W2005655584 hasConceptScore W2005655584C126322002 @default.
• W2005655584 hasConceptScore W2005655584C143998085 @default.
• W2005655584 hasConceptScore W2005655584C168563851 @default.
• W2005655584 hasConceptScore W2005655584C207103383 @default.
• W2005655584 hasConceptScore W2005655584C2776256026 @default.
• W2005655584 hasConceptScore W2005655584C2776694085 @default.
• W2005655584 hasConceptScore W2005655584C2777063308 @default.
• W2005655584 hasConceptScore W2005655584C2778239845 @default.
• W2005655584 hasConceptScore W2005655584C2780258809 @default.
• W2005655584 hasConceptScore W2005655584C2780350996 @default.
• W2005655584 hasConceptScore W2005655584C2781413609 @default.
• W2005655584 hasConceptScore W2005655584C31760486 @default.
• W2005655584 hasConceptScore W2005655584C44249647 @default.
• W2005655584 hasConceptScore W2005655584C61943457 @default.
• W2005655584 hasConceptScore W2005655584C71924100 @default.
• W2005655584 hasLocation W20056555841 @default.
• W2005655584 hasLocation W20056555842 @default.

• next